SCYNEXIS, Inc. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount
SCYNEXIS, Inc. (SCYX) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount of $280.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-04.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost · last filed 2026-03-04
- SCYNEXIS, Inc. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2025 was $280.00K, a 207.69% increase from fiscal 2024.
- SCYNEXIS, Inc. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2024 was $91.00K.
- SCYNEXIS, Inc. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2023 was -$26.00K, a 121.14% decline from fiscal 2022.
- SCYNEXIS, Inc. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2022 was $123.00K, a 7.89% increase from fiscal 2021.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount 12 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount 12 month as first filed |
|---|---|---|
| 2025-12-31 | $280.00K 10-K · filed 2026-03-04 | |
| 2024-12-31 | $91.00K 10-K · filed 2026-03-04 | |
| 2023-12-31 | -$26.00K 10-K · filed 2025-03-12 | |
| 2022-12-31 | $123.00K 10-K · filed 2024-03-28 | |
| 2021-12-31 | $114.00K 10-K · filed 2023-03-31 | |
| 2020-12-31 | $96.00K 10-K · filed 2022-03-29 | |
| 2019-12-31 | $100.00K 10-K · filed 2021-03-29 | |
| 2018-12-31 | $94.00K 10-K · filed 2020-03-11 | |
| 2017-12-31 | $35.00K 10-K · filed 2019-03-14 | |
| 2016-12-31 | $215.00K 10-K · filed 2018-03-13 | |
| 2015-12-31 | $15.00K 10-K · filed 2017-03-13 | |
| 2014-12-31 | $268.00K 10-K · filed 2017-03-13 | $322.00K 10-K · filed 2015-03-30 |
| 2013-12-31 | $41.00K 8-K · filed 2015-10-30 | $57.00K 10-K · filed 2015-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |